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The objective of this research is to gain a greater understanding
of the cause of fasting and postprandial hyperglycemia in people
with type 2 diabetes. Endogenous glucose production is exces-
sive before eating and fails to appropriately suppress after eating
in people with type 2 diabetes. This is due in part to impaired
insulin-induced suppression of endogenous glucose production,
which is observed early in the evolution of type 2 diabetes.
Increased rates of gluconeogenesis and perhaps glycogenolysis
contribute to hepatic insulin resistance. Insulin-induced stimula-
tion of hepatic glucose uptake and hepatic glycogen synthesis are
reduced in people with type 2 diabetes primarily due to de-
creased uptake of extracellular glucose presumably because of
inadequate activation of hepatic glucokinase. Delayed insulin
secretion results in higher peak glucose concentrations particu-
larly when suppression of glucagon is impaired, whereas insulin
resistance prolongs the duration of hyperglycemia, which can be
marked when both hepatic and extra-hepatic insulin resistance
are present.
The premise of these studies, as well as those performed by many
other investigators, is that an understanding of the pathogenesis
of type 2 diabetes will enable the development of targeted
therapies that are directed toward correcting speciﬁc metabolic
defects in a given individual. I, as well as many other investiga-
tors, believe that such therapies are likely to be more effective
and to have a lower risk than would occur if everyone were
treated the same regardless of the underlying cause of their
hyperglycemia. While we do not yet have sufﬁcient knowledge to
truly individualize therapy, in my opinion this approach will be
the norm in the not too distant future. Diabetes 59:2697–2707,
2010
T
he discovery of insulin by Dr. Frederick Banting
and Charles Best forever changed the lives of
people with diabetes. When properly used, insu-
lin prevents death from ketoacidosis in people
with type 1 diabetes and reduces the symptoms from
severe hyperglycemia in people with type 2 diabetes.
Unfortunately, as it is currently used, insulin does not
completely prevent the chronic microvascular or macro-
vascular complications of diabetes. This likely is because
insulin, as well as all other available therapies, does not
fully normalize glucose, or for that matter, lipid or protein
metabolism. The premise of the research that my collab-
orators and I have conducted over the years is that the
only way to maximize the beneﬁt and minimize the risk is
to tailor therapy to each individual’s needs, and the only
way to do so is to understand the cause of hyperglycemia
in that particular person. While much remains to be
learned, I think we have moved a long way toward this
goal. The data that I will review in this article primarily
focuses on the cause of fasting and postprandial hypergly-
cemia in type 2 diabetes. However, in general, the princi-
ples also pertain to people with type 1 diabetes.
Figure 1 shows the results from a series of experiments
conducted by Dr. Peter Butler in which the pattern of
change in glucose, insulin, and glucagon concentrations in
people with type 2 diabetes were compared with those
observed in age-, sex-, and weight-matched nondiabetic
subjects (1). Fifty grams of glucose was ingested at time
zero. Glucose concentrations in the nondiabetic subjects
averaged 5 mmol/l before glucose ingestion, increased to
only 8 mmol/l after glucose ingestion, and returned to
preprandial concentrations within 2 h. The reason why
this occurred was because insulin concentrations rapidly
increased as glucose rose reaching a peak within 30 min of
glucose ingestion. Furthermore, glucagon concentrations
fell as glucose rose and rose as glucose fell back to
preprandial concentrations.
The situation is quite different in people with diabetes.
People with so-called mild type 2 diabetes have both
fasting and postprandial hyperglycemia. In these studies,
fasting glucose averaged 7.2 mmol/l before glucose in-
gestion and increased to 11 mmol/l after glucose inges-
tion. Despite higher glucose concentrations, peak insulin
concentrations did not differ from those observed in the
nondiabetic subjects. Furthermore, they were not
achieved until 2 h after glucose ingestion. People with
so-called severe type 2 diabetes have still higher fasting
glucose concentrations, in this instance 10 mmol/l, and
experience marked and prolonged hyperglycemia after
eating. Once again, insulin secretion was delayed and peak
insulin concentrations did not occur until 2 h after glucose
ingestion. In addition, insulin concentrations during the
2 h after eating were lower than those observed in either
people with mild diabetes or in people who did not have
diabetes. Glucagon concentrations tended to be higher in
people with either mild or severe diabetes before glucose
ingestion and did not suppress and, if anything, paradox-
ically increased after glucose ingestion.
The data from this study (1), as well as those from
studies conducted by many other investigators (2–8),
established that insulin and glucagon secretion are abnor-
mal in people with type 2 diabetes following carbohydrate
ingestion. Insulin secretion is decreased and delayed, and
glucagon does not suppress. The question then arises as to
whether these abnormalities, either alone or in combina-
tion with insulin resistance, cause hyperglycemia. If so, to
what extent do alterations in hepatic glucose metabolism
contribute to fasting and postprandial hyperglycemia?
Figure 2 shows a simpliﬁed portrayal of glucose metab-
olism in the postabsorptive state (9). Following an over-
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stream and is taken up by insulin-sensitive tissues such as
muscle and tissues with limited response to insulin such as
the brain. Glucose released from the liver is derived from
the breakdown of glycogen and the synthesis of new
glucose via the gluconeogenic pathway. The difference
between the rate of glucose entering and the rate of
glucose leaving the blood stream determines whether
glucose rises, falls, or remains the same. Things become
more complicated after eating. Glucose derived from a
meal enters the portal vein after absorption from the gut.
It then can pass through the liver and be released into
systemic circulation, incorporated into glycogen via the
direct pathway, or ﬁrst degraded to three carbon precur-
sors, such as lactate and alanine, then resynthesized via
the indirect gluconeogenic pathway back to glucose-6-
phospate, which in turn can then be either incorporated
into glycogen or dephosphorylated and released into the
systemic circulation as glucose.
In order to determine why glucose concentrations are
too high in people with type 2 diabetes both before and
after eating, Dr. Dick Firth used a multiple tracer approach
to simultaneously measure the total rate of glucose ap-
pearance as well as its components, which are the rate of
appearance of the ingested glucose and the rate of endog-
enous glucose production (10). The upper panel in Fig. 3
shows the total rate of glucose appearance. As is evident,
the rate of glucose appearance was higher in the people
with type 2 diabetes before and after glucose ingestion.
Thus, too much glucose entered the systemic circulation
both before and after eating. The systemic rate of appear-
ance of the ingested glucose, measured by tracing the rate
of appearance of a tracer contained in the meal, is shown
in the middle panel of Fig. 3. Somewhat to our surprise, the
rate of appearance of the ingested glucose did not differ
between groups. Therefore, the excessive rise in postpran-
dial glucose concentrations was not due to too much
glucose entering from the gut. However, since the glucose
concentrations were markedly elevated in the people with
diabetes and since hyperglycemia stimulates hepatic glu-
cose uptake (11–14), these data should not be interpreted
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FIG. 1. Glucose (upper panel), insulin (middle panel), and glucagon
(lower panel) concentrations observed in people who did not have
diabetes, had mild type 2 diabetes or had severe type 2 diabetes. Fifty
grams of glucose was ingested at time zero (1).
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FIG. 2. Simpliﬁed portrayal of glucose metabolism in the postabsorptive (upper panel) and postprandial (lower panel) states (9).
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mal in type 2 diabetes.
What then was the cause of the excessive rate of glucose
appearance? The rates of endogenous glucose production
are shown in the lower panel of Fig. 3. Endogenous
glucose production was higher in the diabetic subjects
than in the nondiabetic subjects before eating. In addition,
whereas endogenous glucose production rapidly de-
creased in the nondiabetic subjects after glucose inges-
tion, suppression of endogenous glucose production was
slower in the people with diabetes and required approxi-
mately 6 h for a nadir to be reached. The excess amount of
glucose released due to slower suppression of endogenous
glucose production entirely accounted for the higher post-
prandial rates of glucose appearance (10).
What about glucose disappearance? Was hyperglycemia
due to lower rates in the diabetic subjects? As is evident
from this side, the answer is no. As is evident from the
upper panel of Fig. 4, if anything the rates of glucose
disappearance were higher in the diabetic subjects than in
the nondiabetic subjects both before and after glucose
ingestion. Urinary glucose loss and muscle glucose uptake
both contribute to glucose disappearance. Urinary glucose
loss can be substantial when glucose concentrations ex-
ceed the renal glucose threshold as commonly happens
after eating. To gain insight regarding muscle glucose
uptake, Dr. Firth used the forearm catheterization method
to measure forearm glucose uptake. As is evident from the
lower panel of Fig. 4 in contrast to the higher rates of total
body glucose disappearance, forearm glucose uptake did
not differ in the diabetic and nondiabetic subjects (10).
Taken together, these data indicate that people with type
2 diabetes have excessive rates of endogenous glucose
production both before and after eating contributing to
both fasting and postprandial hyperglycemia. In addition,
while meal appearance and muscle glucose uptake did not
differ in the diabetic and nondiabetic subjects, they were
not appropriate for the prevailing glucose concentration.
The obvious next question was why was endogenous
glucose production increased in people with type 2 diabe-
tes? Is this due to hepatic insulin resistance? As shown in
Fig. 5, Dr. Rita Basu addressed this question by clamping
glucose at 8 mmol/l, a concentration commonly ob-
served after eating, which is sufﬁciently high to stimulate
hepatic glucose uptake but not so high as to fully suppress
endogenous glucose production (15). Glucose concentra-
tions were maintained at this level by an infusion of
glucose in people with type 2 diabetes or in people who
did not have diabetes. Insulin was infused at rates that
resulted in insulin concentrations that spanned the physi-
ologic range. Somatostatin also was infused in order to
inhibit hormone secretion along with replacement
amounts of glucagon to ensure that portal insulin and
glucagon concentrations were constant and equal through-
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FIG. 3. Rates of total body glucose appearance (upper panel), meal-
derived glucose appearance (middle panel), and endogenous glucose
production (lower panel) observed in people with or without type 2
diabetes. Fifty grams of glucose was ingested at time zero (10).
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subjects.
Rates of endogenous glucose production present during
the ﬁnal 30 min of each insulin infusion are shown in the
upper panel of Fig. 6. Endogenous glucose production was
suppressed in the people who did not have diabetes when
insulin was increased from 150 to 300 pmol with no further
suppression being observed when insulin was subse-
quently increased to 600 pmol. In contrast, despite
matched glucose and insulin concentrations, endogenous
glucose production was higher in the diabetic subjects
than in the nondiabetic subjects at insulin concentrations
of 150 pmol/l indicating hepatic insulin resistance. Endog-
enous glucose production progressively decreased when
insulin concentrations were increased to 300 and then to
600 pmol/l. Of note, while the rates of endogenous glucose
production were slightly higher in the people with diabe-
tes, the differences were no longer signiﬁcant at insulin
concentrations above 150 pmol/l. Thus, people with type 2
diabetes have hepatic insulin resistance. These data also
explain why hepatic insulin resistance will be missed
when insulin action only is assessed at high insulin con-
centrations. A different pattern is observed for glucose
disappearance. As shown in the lower panel of Fig. 6,
glucose disappearance progressively increased in both
groups when insulin concentrations were increased from
150 to 300 to 600 pmol/l. However, glucose disappearance
was lower in the people with diabetes at all three insulin
concentrations.
Why was insulin-induced stimulation of glucose disap-
pearance lower in the people with diabetes? Is insulin-
induced stimulation of hepatic glucose uptake, muscle
glucose uptake, or a combination of both decreased in
people with type 2 diabetes? In order to address this
question, Dr. Ananda Basu used the splanchnic catheter-
ization method, whose development was pioneered by Dr.
John Wahren (16). With this method, blood samples are
simultaneously obtained from an artery and from the
hepatic vein. Splanchnic blood ﬂow is measured by infus-
ing indocyanine green. Since both ﬂow and glucose con-
centration are known, net splanchnic glucose balance
(NSGB) (Fig. 7) can be calculated by subtracting the
amount of glucose leaving the splanchnic bed from the
amount of glucose entering. Splanchnic glucose uptake
(SGU) also can be calculated if a glucose tracer is infused.
For example, if 10 labeled molecules of glucose enter the
splanchnic bed and 9 leave, then SGU must have been one.
Since the ratio of labeled to unlabeled glucose in the artery
is known, total SGU can be determined. Splanchnic glu-
cose production (SGP) then is calculated as the algebraic
sum of NSGB and SGU.
Figure 8 shows SGP measured in the presence of
comparably elevated glucose and insulin concentrations in
the diabetic and nondiabetic subjects. The pattern is
virtually identical to that observed with endogenous glu-
cose production in that the rate of SGP was increased in
the people with type 2 diabetes at low insulin concentra-
tions but no longer differed from people who did not have
diabetes at higher insulin concentrations (16). These data
indicate that insulin-induced suppression of SGP is im-
paired in people with type 2 diabetes. Since the liver is
presumed to be the primary source of SGP, these data
strongly imply that people with type 2 diabetes have
increased rates of hepatic glucose release.
Is insulin-stimulated hepatic glucose uptake also im-
paired in people with type 2 diabetes? Fig. 9 shows that it
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the people with type 2 diabetes at low insulin concentra-
tions and signiﬁcantly lower at higher insulin concentra-
tions. The same pattern was observed for leg glucose
uptake, shown in the lower panel, with leg glucose uptake
being slightly lower at low insulin concentrations and
signiﬁcantly lower at higher insulin concentrations. When
total muscle mass was estimated using measurements
obtained with dual-energy X-ray absorptiometry scanning
under these experimental conditions, muscle accounted
for approximately two-thirds and liver accounted for one-
third of the decrease in total body glucose disappearance
that was observed in the people with type 2 diabetes (16).
Why is SGU decreased in people with type 2 diabetes?
To gain insight into this question, Dr. Andy Basu used a
method pioneered by the late Dr. Bernie Landau and
colleagues (17) where acetaminophen is used to sample
the hepatic uridine-5-diphosphate (UDP)-glucose pool dur-
ing the infusion of labeled galactose. A schematic of this
method is shown in Fig. 10. When infused in trace
amounts, galactose is converted to UDP-galactose within
hepatocyte, which in turn equilibrates with the UDP-
glucose pool. Enrichment of UDP-glucose can be deter-
mined by giving acetaminophen and measuring the
enrichment of UDP-glucuronide in the urine. Since UDP-
glucose is the obligate precursor of glycogen, ﬂux through
the UDP-glucose pool into glycogen can be calculated. The
enrichment of the intravenously infused glucose tracer
also can be measured in the same manner allowing esti-
mation of the proportion of the hepatic UDP-glucose pool
that is derived from the uptake of extracellular glucose.
As is evident in Fig. 11, UDP ﬂux was lower in the
people with diabetes implying decreased rates of hepatic
glycogen synthesis. Of particular interest, the decrease in
UDP glucose ﬂux was entirely accounted for by a decrease
in the rate of uptake of extracellular glucose with no
difference in the proportion derived from intracellular
sources. Since phosphorylation of glucose by glucokinase
is the rate limiting step in the uptake of extracellular
glucose by the liver (18,19), these data strongly suggest a
defect in hepatic glucokinase activity. This conclusion is
supported by studies that have shown decreased activity
of this enzyme in people with type 2 diabetes (20) and by
the observation that hepatic glucose uptake is reduced in
people with genetic defects in glucokinase activation (21).
Thus, people with type 2 diabetes have excessive rates of
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decreased hepatic glycogen synthesis, and decreased up-
take of extracellular glucose.
These data established that endogenous glucose produc-
tion is increased in people with type 2 diabetes. However
these studies (1,10,16) and many other studies in the
literature at that time (22–27) were performed in people
whose fasting glucose concentrations generally were sub-
stantially above the nondiabetic range (e.g., 10–13 mmol/
l). The question then arose as to whether endogenous
glucose production is increased in people with mild as
well as severe type 2 diabetes. If so, it would suggest that
increased rates of endogenous glucose production contrib-
ute to rather than are caused by the abnormal metabolic
milieu that accompanies elevated glucose concentrations.
To address this question, Dr. Rita Basu (28) performed
hyperglycemic, hyperinsulinemic clamps in people with
so-called severe diabetes, whose fasting glucose concen-
trations averaged 12 mmol/l; in people with mild diabe-
tes, whose fasting glucose concentrations averaged 8
mmol/l; and in people who did not have diabetes, whose
fasting glucose concentrations averaged 5 mmol/l (Fig.
12 upper panel). On each occasion, Dr. Rita Basu began an
infusion of somatostatin, insulin, and glucagon at time
zero to be sure that portal concentrations of insulin and
glucagon were constant and equal in all groups during the
clamp. She also infused sufﬁcient glucose to raise glucose
concentrations to 11 mmol/l in the subjects with either
mild diabetes or no diabetes. Glucose concentrations in
the people with severe diabetes remained elevated at
concentrations that averaged 12 mmol/l. Fasting insulin
concentrations in the people with mild diabetes were
higher than those present in the people who did not have
diabetes implying higher hepatic insulin concentrations
(Fig. 12 lower panel). In contrast, insulin concentrations
were comparable in all groups during the clamp. The
somatostatin infusion and glucagon infusions resulted in
near complete suppression of C-peptide and constant but
equal plasma glucagon concentrations in both groups
(data not shown).
The left side of Fig. 13 shows the rates of endogenous
glucose production that were present before the clamp.
Consistent with previous studies (22–26) and those dis-
cussed above (1,10,16,27), endogenous glucose production
was increased in people with severe diabetes but did not
differ in people with mild diabetes or no diabetes. How-
ever, since people with mild diabetes had higher glucose
and insulin concentrations, this implied abnormal regula-
tion of endogenous glucose production. This became
evident during the clamp. As shown on the right side of
Fig. 13, when glucose and insulin concentrations were
matched, endogenous glucose production was higher in
both the mild and severe diabetic groups. Dr. Gerlies Bock
(29) recently used a similar experimental design to estab-
lish that insulin-induced suppression of endogenous glu-
cose production also is impaired in people with pre-
diabetes (data not shown). Thus, abnormal regulation of
hepatic glucose metabolism occurs early in the evolution
of type 2 diabetes, strongly suggesting it is involved in the
pathogenesis of the disease.
Increased rates of endogenous glucose production can
be caused by increased rates of gluconeogenesis, in-
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Figure 14 (upper panel) shows the rates of gluconeogen-
esis measured using the deuterated water method that was
pioneered by Dr. Bernie Landau (30). This method is based
on the fact that following the ingestion of deuterated
water, the ﬁfth carbon of glucose is labeled with deute-
rium during gluconeogenesis, whereas the second carbon
of glucose is labeled with deuterium during both the
gluconeogenesis and glycogenolysis (30). While the as-
sumptions of this method continue to be evaluated (31,32),
it is widely accepted as providing an index of gluconeo-
genesis. Consistent with previous studies (23,25), the data
on the left side of Fig. 14 indicate that gluconeogenesis
was increased in the people with severe diabetes before
the clamp. However, as shown on the right side of Fig. 14,
perhaps due to the fact that glucagon was lowered to
comparable levels by the somatostatin infusion, the rates
of gluconeogenesis that were present during the clamp no
longer differed among the groups.
Rates of glycogenolysis can be estimated by subtracting
the rate of gluconeogenesis from the rate of endogenous
glucose production. As shown in the lower panel of Fig.
14, the rate of glycogenolysis was increased in the people
with severe diabetes before the clamp but did not differ in
people with mild diabetes or no diabetes. However, hyper-
glycemia is known to be a potent suppressor of glycogen-
olysis (33). This is evident from the data shown on the
right side of Fig. 14 since rates of glycogenolysis in the
people who did not have diabetes were almost completely
suppressed when their glucose was raised to 200 mg/dl. In
contrast, minimal suppression occurred in the people with
either mild or severe diabetes, indicating that the rates of
glycogenolysis were not inappropriate for the prevailing
glucose and insulin concentrations.
What about insulin secretion? Do alterations in insulin
secretion and insulin action have the same effect on
postprandial glucose concentrations? Dr. Ananda Basu
attempted to answer this question by determining the
metabolic effects of diabetic and nondiabetic insulin pro-
ﬁles in insulin-sensitive and insulin-resistant people (34).
Figure 15 shows the insulin concentrations that were
observed after Dr. Andy Basu fed a carbohydrate contain-
ing meal to people who had either severe type 2 diabetes
or no diabetes. As anticipated, the meal resulted in a
prompt increase in insulin concentrations in people who
did not have diabetes with levels peaking at 45 min. In
contrast, there was a delay in insulin release in the people
with type 2 diabetes with concentrations not reaching a
peak until approximately 2 h after eating.
Dr. Andy Basu then studied separate groups of lean
nondiabetic subjects, obese nondiabetic subjects, and
obese subjects with type 2 diabetes on two occasions. On
each occasion he infused somatostatin to inhibit endoge-
nous insulin secretion and used a computer to infuse the
identical amount of insulin as either a nondiabetic or
diabetic proﬁle (34). Figure 16 shows the resultant insulin
concentrations. The insulin concentrations peaked at 30
min during the nondiabetic proﬁle and at 120 min during
the diabetic proﬁle. Note that this resulted in substantially
lower insulin concentrations during the ﬁrst hour of the
diabetic insulin proﬁle in all three groups. Dr. Basu also
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hormone were started at time zero (34).
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the meal appearance rate that normally occurs following
ingestion of a meal containing 50 g of glucose. Thus, both
groups received identical amounts of glucose and insulin
on all occasions; only the pattern of the insulin infusion
differed. Figure 17 shows the resultant glucose concentra-
tions. The diabetic insulin proﬁle caused a higher peak
glucose concentration than the nondiabetic proﬁle did in
all three groups. However, this difference was transient
with glucose concentrations falling within three hours to
values that no longer differed from those observed during
the nondiabetic insulin proﬁle. These data indicate that a
delay in the rate of the rise of insulin resulted in a higher
peak glucose concentration but only minimally prolonged
the duration of hyperglycemia.
In order to evaluate the effects of the differences in
insulin action, the results observed during the nondiabetic
proﬁle are shown in the upper panel of Fig. 18, and those
observed during the diabetic proﬁle are shown in the
lower panel. Peak glucose concentrations did not differ in
the lean and obese subjects regardless of whether insulin
was infused as a nondiabetic proﬁle or a diabetic proﬁle.
However, the duration of hyperglycemia was more pro-
longed in the obese nondiabetic subjects then in the lean
nondiabetic subjects. The duration of hyperglycemia was
even more prolonged in the people with type 2 diabetes
during both the nondiabetic and the diabetic insulin pro-
ﬁles. Thus, insulin resistance prolonged the duration of
hyperglycemia but had a minimal effect on the peak
glucose concentration. Note that the glucose concentra-
tions were substantially higher in the obese diabetic
subjects than in the obese nondiabetic subjects.
Why did this happen? Fig. 19 shows the rates of glucose
clearance in the lean and obese individuals who did not
have diabetes (34). Despite identical insulin concentra-
tions and higher glucose concentrations, the rates of
glucose clearance were lower in the obese individuals
documenting the presence of insulin resistance. Glucose
clearance also was lower in the obese subjects with type 2
diabetes. However, the rates did not differ from those
observed in the obese subjects who did not have diabetes
whether measured during the nondiabetic or diabetic
insulin proﬁles. Therefore, the higher glucose concentra-
tions in the obese diabetic were not due to lower rates of
glucose clearance.
Figure 20 shows the rates of endogenous glucose pro-
duction. Endogenous glucose production was comparably
suppressed in the lean and obese nondiabetic subjects. On
the other hand, suppression of endogenous glucose pro-
duction was markedly impaired in the subjects with type 2
diabetes whether measured during the nondiabetic or the
diabetic insulin proﬁles. Thus, a delay in insulin secretion
results in higher peak glucose concentrations, and a
decrease in insulin action results in prolonged hypergly-
cemia, which is particularly severe when decreased glu-
cose clearance is accompanied by excessive rates of
endogenous glucose production.
What about glucagon? Does the lack of suppression of
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illustrated in the bottom panel of Fig. 1, glucose ingestion
suppresses glucagon concentrations in people who do not
have diabetes. In contrast, glucagon concentrations either
do not decrease or paradoxically increase in people with
type 2 diabetes (1,3,8,35). Can the 40–50 pg/ml difference
in glucagon concentration that arises from the lack of
suppression of glucagon cause postprandial hyperglyce-
mia? In order to address this question, Dr. Pankaj Shah
studied a group of healthy nondiabetic subjects on two
occasions (36). He infused insulin as a nondiabetic insulin
proﬁle on both occasions. On one occasion, glucagon was
suppressed; on the other occasion, it was not. Dr. Shah
used the same experimental design in a separate set of
subjects except he infused a diabetic insulin proﬁle on
both occasions. Figure 21 shows that the resultant insulin
concentrations were virtually identical on the suppressed
and the nonsuppressed study days. However, as expected,
the nondiabetic proﬁle resulted in insulin concentrations
that peaked at 30 min (upper panel), whereas the diabetic
proﬁle resulted in insulin concentrations that peaked at
120 min (lower panel).
Figure 22 shows the glucagon concentrations that were
achieved during the experiments. To create these patterns,
Dr. Shah infused somatostatin from 0 to 360 min on both
occasions in order to inhibit glucagon release. On one
occasion, he infused glucagon at a rate of 0.65 ng/kg/min
throughout the experiment, which resulted in a slight
increase in peripheral glucagon concentrations. Since en-
dogenous secretion decreased, this meant that portal
glucagon concentrations either did not change or mini-
mally increased during the experiment. In contrast, on the
other occasion he delayed starting the glucagon infusion
until 120 min. This resulted in an approximate 50 pg/ml
difference in glucagon on the 2 study days that was only
present during the ﬁrst2ho ft h eexperiment (36).
The upper panel of Fig. 23 shows the glucose concen-
trations that resulted when 35 g of glucose also was
infused in the same prandial proﬁle as was used in the
experiments by Basu et al. (34). Of note, in the presence of
the nondiabetic proﬁle, the peak glucose concentrations
were the same whether or not glucagon was suppressed.
While the glucose area above basal was signiﬁcantly
higher on the suppressed than the nonsuppressed study
days, the difference was small.
An entirely different outcome was observed in the
presence of the diabetic insulin proﬁle. As shown in the
lower panel of Fig. 23, the lack of suppression of glucagon
resulted in peak glucose concentrations that were 50–60
mg/dl higher than were observed when glucagon was
suppressed. Also of interest, despite the delayed rise in
insulin that occurred during the diabetic proﬁle, glucose
concentrations on the suppressed glucagon study day
peaked at only 145 mg/dl. These data suggest that an agent
that suppresses glucagon in the presence of a rapid
increase in insulin concentration will have a minimal effect
on postprandial glucose concentrations. On the other
hand, if insulin secretion is delayed, as typically occurs in
people with diabetes, then an agent that suppresses glu-
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concentrations.
As indicated in Fig. 24, many factors contribute to
fasting and postprandial hyperglycemia. People with type
2 diabetes have excessive rates of endogenous glucose
production that fail to appropriately suppress after eating
(10,16,28). Rates of gluconeogenesis and perhaps glyco-
genolysis are increased early in the evolution of diabetes
(28,37). Insulin-induced stimulation of hepatic glucose
uptake is impaired in people with type 2 diabetes. This
leads to lower rates of hepatic glycogen synthesis primar-
ily due to reduced uptake of extracellular glucose presum-
ably because of inadequate activation of hepatic
glucokinase (16,38). Delayed insulin secretion results in
higher peak glucose concentrations particularly when
suppression of glucagon is impaired, whereas insulin
resistance prolongs the duration of hyperglycemia, which
can be marked when both hepatic and extra-hepatic
insulin resistance are present (36).
The premise of all of these studies, as well as others that
my colleagues and I have performed, is that an under-
standing of the pathogenesis of type 2 diabetes enables the
development of targeted therapies that are directed to-
ward correcting speciﬁc metabolic defects in a given
individual. I, as well as many other investigators, believe
that such therapies are likely to be more effective and have
a lower risk than would occur if everyone were treated the
same regardless of the underlying cause of their hypergly-
cemia. While we do not yet have sufﬁcient knowledge to
truly individualize therapy, in my opinion this approach
will be the norm in the not too distant future.
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